BeOne Medicines publishes clinical trial portfolio presentation
ONC•BeOne Medicines published its Q3 2026 clinical trials portfolio presentation, describing sonrotoclax programs, a 500-patient tacabrutideg trial and new pivotal programs in ovarian and liver cancers.
1. Trial portfolio update
BeOne Medicines published its Q3 2026 clinical trials portfolio presentation. Sonrotoclax holds U.S. approval for relapsed or refractory mantle cell lymphoma, and its EU submission has been accepted; Phase 3 trials in relapsed or refractory blood cancers remain enrolling.
2. Other programs
A Phase 3 trial of tacabrutideg against pirtobrutinib in relapsed or refractory CLL/SLL is enrolling 500 patients. New pivotal programs include a B7-H4 ADC in first-line ovarian cancer maintenance and a GPC3-targeted therapy in second-line or later liver cancer.
